A unique combination of nutritionally active ingredients can prevent several key processes associated with atherosclerosis in vitro by Moss, Joe W. E. et al.
RESEARCH ARTICLE
A Unique Combination of Nutritionally Active
Ingredients Can Prevent Several Key
Processes Associated with Atherosclerosis
In Vitro
JoeW. E. Moss1, Thomas S. Davies1, Iveta Garaiova2, Sue F. Plummer2,
Daryn R. Michael2*, Dipak P. Ramji1
1 School of Biosciences, Cardiff University, Cardiff, United Kingdom, 2 Cultech Limited, Baglan Industrial
Park, Port Talbot, United Kingdom
* darynm@cultech.co.uk
Abstract
Introduction
Atherosclerosis is the underlying cause of cardiovascular disease that leads to more global
mortalities each year than any other ailment. Consumption of active food ingredients such
as phytosterols, omega-3 polyunsaturated fatty acids and flavanols are known to impart
beneficial effects on cardiovascular disease although the combined actions of such agents
in atherosclerosis is poorly understood. The aim of this study was to screen a nutritional
supplement containing each of these active components for its anti-atherosclerotic effect on
macrophages in vitro.
Results
The supplement attenuated the expression of intercellular adhesion molecule-1 and macro-
phage chemoattractant protein-1 in human and murine macrophages at physiologically rel-
evant doses. The migratory capacity of human monocytes was also hindered, possibly
mediated by eicosapentaenoic acid and catechin, while the ability of foam cells to efflux
cholesterol was improved. The polarisation of murine macrophages towards a pro-
inflammatory phenotype was also attenuated by the supplement.
Conclusion
The formulation was able to hinder multiple key steps of atherosclerosis development
in vitro by inhibiting monocyte recruitment, foam cell formation and macrophage polarisation
towards an inflammatory phenotype. This is the first time a combination these ingredients
has been shown to elicit such effects and supports its further study in preclinical in vivo
models.
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Introduction
Cardiovascular disease (CVD) related events, such as myocardial infarction (MI) and stroke,
are the leading causes of global death every year. The World Health Organisation estimated
that there were approximately 17.5 million deaths from CVD-related events in 2012 [1] and
this figure has been predicted to rise to 23.3 million by 2030 due to the global increase in obe-
sity and diabetes, and the incorporation of a westernised lifestyle in developing countries [1].
Atherosclerosis is the major underlying cause of CVD, emphasising the need to develop novel
approaches to support disease prevention.
Atherosclerosis is a chronic, inflammatory disease of the vasculature characterised by the
formation of lipid laden foam cells [2–5]. The initial trigger of atherosclerosis is the accumula-
tion and trapping of ApoB-containing lipoproteins, such as low-density lipoprotein (LDL), in
the intima of medium and large arteries [3–5]. Modification of the trapped LDL, particularly
oxidised (ox)-LDL, instigates an inflammatory response in the nearby endothelial cells (ECs)
[3–5]. Activated ECs then release pro-inflammatory cytokines and chemokines, such as macro-
phage chemoattractant protein-1 (MCP-1), which direct circulating monocytes and T lympho-
cytes to the site of oxLDL accumulation [3–5]. Additionally, the ECs also begin to express cell
adhesion molecules on their surface, including intercellular adhesion molecule-1 (ICAM-1)
and vascular cell adhesion molecule-1 (VCAM-1), as well as P- and E-selectins, which aid the
adhesion of circulating monocytes to the site of oxLDL accumulation [3–5]. Once in the
intima, the monocytes differentiate into macrophages which are then able to uptake oxLDL
and develop into foam cells [3–5]. Over time, the continued and aberrant recruitment of mac-
rophages to the site of insult results in the accumulation of foam cells that eventually develop
into an unstable atherosclerotic plaque that, upon rupture, leads to thrombosis, MI and stroke
[3–5].
Numerous macrophage phenotypes reside within atherosclerotic lesions and this popula-
tion is largely composed of classical M1 or alternative M2 polarised macrophages [3, 5]. Under
normal physiological conditions, M2 polarisation occurs as a result of IL-4 stimulation and is
usually associated with the resolution of inflammation and repair whereas M1 macrophages
are activated by stimuli such as interferon-γ (IFN-γ), lipopolysaccharide (LPS) and oxLDL and
participate in pro-inflammatory actions towards bacterial infections during the innate immune
response [6]. However, due to their pro-inflammatory nature it is thought that the presence of
M1 macrophages in atherosclerotic plaques can drive disease progression [7, 8] and it has been
shown that this macrophage subset often localises to rupture-prone shoulder areas of athero-
sclerotic plaques [8]. Approaches to reduce M1 accumulation may result in more stable athero-
sclerotic plaques and also represent an ideal target for disease intervention.
It has been estimated that approximately 70% of cardiovascular disease related events are
not prevented by the current therapies which includes the use of statins [9]. These are the most
extensively used class of cholesterol lowering therapy for CVD and their primary function is to
inhibit the enzyme 3-hydroxy-3-methylglutaryl-CoA, which catalyses the rate-limiting step in
cholesterol biosynthesis [4]. However, a significant minority of people receiving statins are
unable to lower their LDL levels even at the maximal dose [4] and are prone to adverse side
effects such as increased risk of type 2 diabetes [10, 11] stressing the need to develop novel
approaches to prevent atherosclerosis. It has been known for some time that the consumption
of various active food ingredients can improve cardiovascular health. For example, numerous
epidemiological studies [12, 13] and clinical trials [14, 15] examining the effects of fish oil con-
sumption, particularly the omega-3 polyunsaturated fatty acids (ω-3 PUFAs) eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), have reported lower plasma cholesterol levels
and a reduced risk of a MI. EPA and DHA have also been shown to dampen the inflammatory
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response by macrophages by directly binding to G protein-coupled receptor (GP)-120 present
on the cell surface [16] which is likely to contribute to the observed anti-foam cell effects of
these fatty acids [17]. Flavanoids, a group of secondary plant metabolites that can be found in
foods such as cocoa beans and specific flavonoid subgroups, such as flavanols (catechins), have
also been shown to reduce the expression of pro-inflammatory genes [18], and circulating LDL
levels in vivo [19]. An abundant form of catechin, epigallocatechin-3-gallate, has been shown
to impart an anti-inflammatory effect on macrophages by directly binding to the cell surface
laminin receptor (67LR) [20] and by regulating the expression of a range of trancription factors
including nuclear factor κB (NF-κB) (reviewed extensively in [21]). Phytosterols (PS) are cho-
lesterol homologues found in plants that have been shown to reduce plasma LDL levels in both
observational and clinical studies [22, 23] by competitive exclusion of cholesterol from micellar
space in the intestinal lumen and modulation of enterocyte cholesterol trafficking [24]. PS also
have a direct effect on cholesterol homeostasis in macrophage-derived foam cells by regulating
the expression of key cholesterol transport genes such as ATP-binding cassette transporter
(ABC)A-1 and ABCG-1 [25].
The objective of this study is to assess the ability of a dual-action nutritional supplement
comprised of mixed PS, ω-3 PUFA-rich fish oil and flavanol rich cocoa extract in a readily
absorbable emulsified format [26, 27] to prevent the development of atherosclerosis by, firstly,
reducing the amount of cholesterol absorbed in the intestines by the action of PS, followed by
inhibition of the cellular mechanisms driving the disease after absorption. The supplement has
been designed to present physiologically relevant doses of the active ingredients in a series of
established in vitromodels of atherosclerosis in order to demonstrate efficacy.
Methods
Regents and cell culture
All reagents were purchased from Life Technologies (Paisley, UK), unless otherwise stated.
EPA, DHA, campesterol and β-sitosterol were purchased from Cambridge Biosciences (Cam-
bridge, UK). Stigmasterol and (+)-catechin were purchased from Sigma-Aldrich (Poole, UK).
Human acute monocytic leukemia cell line (THP-1; obtained directly from ECACC, Salisbury,
UK (Catalogue number: 88081201)), primary human monocyte derived macrophages
(HMDM) and Raw264.7 murine macrophage (obtained directly from Sigma-Aldrich, Poole,
UK (Catalogue number: 85062803-VL)) were grown in complete RPMI-1640 (Lonza, Man-
chester, UK) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS), penicillin
(100 U/ml), streptomycin (100 μg/ml) and L-glutamine (2 mmol/l) at 37°C in a humidified
atmosphere containing 5% (v/v) CO2. THP-1 monocytes were differentiated into macrophages
by incubation with 160 nM phorbol-12-myristate-13-acetate (PMA; Sigma-Aldrich, Poole,
UK) for 24 hours to ensure high expression levels of genes implicated in the control of macro-
phage foam cell formation [28, 29]. HMDM were isolated from buffy coats supplied by the
Welsh Blood service using Ficoll-Hypaque purification described elsewhere [29]. Ethical
approval and informed consent for each donor was granted by the Welsh Blood Service for the
use of human blood samples.
Formulation dosage and application to cells
The nutritional supplement formulation (S1 Table) was provided by Cultech Limited (Port
Talbot, UK) as a concentrated stock (500x) designed to deliver each active ingredient at doses
approximating to reported in vivo serum levels with a 1x dose composed of 180 μg/ml fish oil
(delivering 30 μg/ml EPA, 19.7 μg/ml DHA [26]), 56 μg/ml of mixed PS (delivering 10 μg/ml
Stigmasterol [30], 13.9 μg/ml Campsterol, 27.2 μg/ml Sitosterol and 1.672 μg/ml Brassicasterol)
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and 7.25 μg/ml cocoa extract (delivering 5 μmol/ml catechins [31]). A PS-free version of the
formulation was also provided. Fatty acid free bovine serum albumin (BSA; 100 μg/ml per 1x
dose) was included in both formulations to act as a physiologically relevant protein carrier and
to facilitate the emulsification of the formulations and allow their natural dispersion in an
aqueous medium. BSA alone was used as the vehicle control at an appropriate concentration
and the formulation was applied to the cells diluted in complete culture media unless otherwise
stated. EPA, DHA, (+)-catechin, stigmasterol, campsterol and β-sitosterol were applied to the
cells (at doses equivalent to those present in the complete formulation (x1)) in dimethyl sulfox-
ide (DMSO) that was also included at the relevant concentration as the vehicle control for
these experiments.
Cell viability and proliferation assays
The cell supernatants from THP-1 macrophages (4.11x105 cells/cm2) were removed and
assayed for lactate dehydrogenase (LDH) content using the Pierce LDH cytotoxicity assay
(Thermo Scientific, Waltham, USA) in accordance with the manufacturer’s instructions. The
remaining cells were then stained with 0.2% (w/v) crystal violet solution (in 10% (v/v) ethanol)
for 5 minutes at room temperature before washing the cells three times in warm PBS (pH 7.4).
Intracellular crystal violet was then solubilised in 0.1 M NaH2PO4 (in 50% (v/v) ethanol) and
the absorbance was read at 570 nm using a colorimetric spectrophotometer. Viability (LDH
assay) and proliferation (crystal violet) were expressed as a percentage of the BSA vehicle con-
trol that was arbitrarily assigned as 100%.
RNA extraction, reverse transcription, and quantitative PCR
RNA was extracted from THP-1 macrophages (1.28x105 cells/cm2), HMDM (1.28x105 cells/
cm2) or Raw264.7 macrophages (5.13x104 cells/cm2) using RiboZol™ RNA extraction reagent
(Amresco, Solon, US) in accordance with the manufacturer’s instructions and total RNA con-
centrations were quantified using a NanoDrop 2000 spectrophotometer (Thermo Scientific,
Waltham, USA). cDNA was then reverse transcribed from 1000 ng of RNA as previously
described [32]. Quantitative polymerase chain reaction (qPCR) was performed on 10 ng cDNA
using SYBR Green JumpStart™ Taq Readymix™ and 50 nM of each oligonucleotide primer was
used (see S2 Table). Fold changes in gene expression were calculated using 2−(ΔCt1−ΔCt2), where
ΔCt represents the difference between the threshold cycle (Ct) for each target gene and Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) transcript levels for human studies or β-actin
mRNA transcript levels for murine studies. Initial melting (94°C for 120 seconds) was followed
by 40 cycles of melting (95°C for 30 seconds), annealing (60°C for 60 seconds (66°C for Induc-
ible Nitrogen Oxide Synthase (iNOS) and Arginase-2 (Arg2)), and extension (72°C for 60 sec-
onds)). The inclusion of reverse transcriptase negative controls and melting curve analysis in
each experiment confirmed there was no amplification from genomic DNA. The amplicon size
of all primers sets were confirmed by agarose gel electrophoresis (data not shown).
Monocyte Migration
Monocyte migration was assessed by adding undifferentiated THP-1 monocytes (alone or with
formulation or with individual bioactive components; 1x106 cells/ml) to the apical compart-
ment of Falcon1 cell culture inserts (8 μm pore size) that were housed in Falcon1 12-well
companion plates (VWR Jencons, Lutterworth, UK) containing complete RPMI media supple-
mented with MCP-1 (20 ng/ml; Peprotech, London, UK). Following incubation, apical
medium was aspirated and the underside of the porous membrane washed into the wells to
capture all migrating cells. Monocyte numbers present in the basolateral (lower) compartment
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were counted using a haemocytometer and monocyte migration is expressed as a fold-change
compared to the proportion of cells that moved from the apical compartment into the basolat-
eral compartment in response to MCP-1 alone and has been arbitrarily set as 1.0.
Cholesterol efflux assay
Cholesterol efflux assays were carried out following a previously described protocol with minor
adaptations [32]. Briefly, THP-1 macrophages (1.28x105 cells/cm2) were incubated with acety-
lated (Ac)LDL (25 mg/ml; Biotrend, Cologne, Germany) and [4-14C]cholesterol (0.5 mCi/ml;
Amersham, Buckinghamshire, UK) in media containing 0.2% (v/v) fatty acid free BSA for 24
hours before they were treated for a further 24 hours with the previously described media con-
taining Apolipoprotein A-I (ApoA-I) (10 mg/ml; Sigma-Aldrich, Poole, UK) with or without
the formulation. Cell supernatants were then collected and the remaining cells were solubilised
in 0.2 M NaOH. Cholesterol efflux was calculated as the percentage radioactivity in the super-
natant versus total radioactivity (cells and supernatant) as measured by a liquid scintillation
counter. Cholesterol efflux was expressed as a fold change of the vehicle control that was arbi-
trarily assigned as 1.0.
Data analysis
The normality of all data sets was tested using Shapiro-Wilk test for normality and confirmed
with histograms and Q-Q plots. Any required data transformations are stated in the figure leg-
ends. P values were determined using one-way ANOVA with Dunnett T3 (unequal variance)
or Dunnett (equal variance) post-hoc analysis and significance was defined when p<0.05. All
statistics were performed using SPSS statistical software package version 20.0. Data are pre-
sented as means (± standard error of the mean (SEM)).
Results
The formulation does not impart a cytotoxic effect on human
macrophages in vitro
The relative health and activity of the human THP-1 monocyte-derived macrophages in the
presence of the formulation was confirmed by two independent assays. As shown in Fig 1, no
significant differences in cell viability (Fig 1a: LDH assay) or cell proliferation/activity (Fig 1b:
crystal violet assay) were observed in response to 24 hours incubation with the complete for-
mulation (+PS) at a range of doses when compared to the vehicle control.
The formulation inhibits the IFN-γ induced expression of MCP-1 and
ICAM-1 mRNA transcripts in macrophages
MCP-1 and ICAM-1 are both considered to be robust markers of inflammation that are associ-
ated with atherosclerosis [5] and their expression is known to be induced by IFN-γ [33]. To
this end, IFN-γ stimulation significantly increased the transcript levels of MCP-1 (Fig 2a;
7.83-fold increase (p<0.001), Fig 2c; 10.13-fold increase (p<0.001)) and ICAM-1 (Fig 2b;
2.55-fold increase (p = 0.014), Fig 2d; 1.99-fold increase (p = 0.001)) in human THP-1 mono-
cyte-derived macrophages when compared to the vehicle control. However, in the presence of
1x and 2x doses of the complete formulation, significant 71.3% (p = 0.004) and 73.6% reduc-
tions (p = 0.001), respectively, in IFN-γ induced MCP-1 transcript levels were observed when
compared to cells treated with IFN-γ alone (Fig 2a). Likewise, 51.1% (p = 0.108) and 57.5%
(p = 0.010) reductions were observed in IFN-γ induced ICAM-1 expression in response to the
same doses, although the 1x dose failed to reach significance (Fig 2b). As seen is Fig 2c,
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comparable effects were also apparent in response to a formulation that lacked the PS compo-
nent where the 1x and 2x doses were able to significantly reduce IFN-γ induced MCP-1 tran-
script levels by 79.1% (p = 0.001) and 78.2% (p = 0.002), respectively, when compared to the
IFN-γ treated cells. IFN-γ induced ICAM-1 expression was also significantly reduced in the
presence of 1x and 2x doses lacking PS (by 52.8% (p<0.001) and 64.7% (p<0.001) respectively)
when compared to the IFN-γ treated cells (Fig 2d). These effects were partly confirmed in pri-
mary HMDMwhere IFN-γ induced expression of ICAM-1 (1.75-fold increase (p = 0.016)) was
significantly decreased the presence of the complete formulation and that lacking PS by 63.9%
(p = 0.002) and 50.6% (p = 0.013) respectively (Fig 2e). No significant differences were
observed between the complete formulation and that lacking PS for either gene in THP-1 or
HMDM. In addition, the observed changes in MCP-1 and ICAM-1 gene expression also appear
to be conserved in murine Raw264.7 macrophages although slight differences in dosing are
apparent (S1 Fig).
Fig 1. Physiologically relevant doses of the formulation have no detrimental effect on human
macrophage viability or proliferation. Cell viability (a) or proliferation (b) was assessed in PMA
differentiated THP-1 macrophages that were treated with vehicle (vehicle control) or various doses of the
complete formulation (+PS) for 24 hours. Data were normalised to the vehicle control that has been arbitrarily
assigned as 100%. The data are presented as the mean ± SEM from three independent experiments.
Statistical analysis was performed using one-way ANOVAwith Dunnett T3 post-hoc analysis.
doi:10.1371/journal.pone.0151057.g001
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The formulation inhibits the migration of human monocytes towards
MCP-1
The recruitment of monocytes to the activated endothelium in response to chemokines such as
MCP-1 is a critical early step in the development of atherosclerosis [5] and these actions were
confirmed in our system as a significant 6.84-fold induction (p<0.001) in monocyte recruit-
ment in cells treated with MCP-1 alone was observed when compared to the vehicle control
(Fig 3). Upon the inclusion of the complete formulation (1x), monocyte recruitment in
Fig 2. Physiologically relevant doses of the formulation can inhibit the IFN-γ induced expression of MCP-1 and ICAM-1 in humanmacrophages.
Gene transcript levels of MCP-1 (a and c) and ICAM-1 (b, d and e) were assessed in PMA differentiated THP-1 macrophages (a, b, c and d) or HMDM (e) that
were either treated with vehicle (vehicle control) or with IFN-γ (250 U/ml) or IFN-γ (250 U/ml) in the presence of the complete formulation (+PS; a, b and e) or
with IFN-γ (250 U/ml) in the presence of the formulation lacking PS (-PS; c, d and e) for 3 hours. Gene transcript levels were calculated using the comparative
Ct method and normalised to GAPDH levels with values from vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM
from three (a, b, c and d) or four (e) independent experiments. Statistical analysis was performed using a one-way ANOVA with Dunnett T3 post-hoc analysis
on log-transformed data where * p <0.05, ** p <0.01 and *** p <0.001.
doi:10.1371/journal.pone.0151057.g002
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response to MCP-1 was significantly reduced (38.2%, p = 0.001) when compared to cells
treated with MCP-1 alone. Similarly, incubation with the formulation lacking PS resulted in a
37% (p = 0.023) reduction in migration when compared to MCP-1 alone treated cells. No sig-
nificant difference in monocyte migration was observed between the complete formulation and
that lacking PS.
The formulation improves the efflux of cholesterol from human
macrophages
After 24 hours stimulation with ApoA-I, human THP-1 macrophage-derived foam cells were
able to efflux approximately 20.2% of their intracellular radiolabelled cholesterol content
(Fig 4). Significant fold changes in cholesterol efflux were observed in cells which were either
co-incubated with the complete formulation (1x) or the formulation lacking PS (1x) with
ApoA-I, 1.61 (p = 0.002) and 1.53 (p = 0.001) respectively, when compared to those treated
with ApoA-I alone. No significant differences in cholesterol efflux were observed between the
complete formulation and that lacking PS.
The formulation attenuates the expression of M1 phenotype markers in
murine macrophages
Co-stimulation of Raw264.7 macrophages with IFN-γ and LPS significantly induced the
expression of iNOS (Fig 5a, p<0.001) and Arg2 (Fig 5b, p<0.001), two robust markers of M1
phenotype [34]. Inclusion of the complete formulation (1x) significantly decreased the
Fig 3. A physiologically relevant dose of the formulation can inhibit MCP-1 inducedmigration of humanmonocytes. Cellular migration was
assessed using THP-1 monocytes that were treated with vehicle (vehicle control) or treated with MCP-1 (20 ng/ml) alone or with MCP-1 (20 ng/ml) in the
presence the complete formulation (+PS) or with MCP-1 (20ng/ml) in the presence the formulation lacking PS (-PS) for 3 hours. Monocyte migration is
expressed as a fold-change compared to the proportion of cells that moved from the apical compartment into the basolateral compartment in response to
MCP-1 alone that has been arbitrarily set as 1. The data are presented as the mean ± SEM from four independent experiments. Statistical analysis was
performed using a one-way ANOVA with Dunnett T3 post-hoc analysis where ** p <0.01 and *** p <0.001.
doi:10.1371/journal.pone.0151057.g003
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expression of both iNOS (Fig 5a) and Arg2 (Fig 5b) by 47.6% (p = 0.004) and 41.5%
(p = 0.015), respectively, when compared to the IFN-γ and LPS treated cells. Likewise, incuba-
tion with the formulation lacking PS (1x) significantly reduced the IFN-γ and LPS mediated
induction of iNOS (Fig 5a) by 44.6% (p = 0.002) whereas a trend towards a 37.2% decrease
(p = 0.056) was observed for Arg2 (Fig 5b). No significant differences in iNOS or Arg2 expres-
sion were observed between the complete formulation and that lacking PS. It should be noted
that murine Raw264.7 macrophages were used in these experiments rather than human THP-1
monocyte-derived macrophages in light of evidence suggesting that PMA differentiation pro-
motes an established population of M1 phenotype [35].
Key bioactive ingredients of the complete formulation can inhibit the
migration of human monocytes towards MCP-1
Similar to that observed in Fig 3, MCP-1 significantly induced (9.61-fold, p<0.001) monocyte
recruitment when compared to the vehicle control (Fig 6). Significant inhibitions of MCP-1
induced monocyte migration were observed in the presence of EPA (52.7%, p = 0.009) or
(+)-catechin (47.5%, p = 0.02) when compared to cells treated with MCP-1 alone. While they
did not reach significance, a trend towards a reduction in monocyte migration was observed in
response to DHA, stigmasterol (SS), campsterol (CS) and β-sitosterol (β-SS).
Discussion
This study shows that a combination of food ingredients can attenuate the expression of two
key pro-atherogenic genes, reduce MCP-1 driven monocyte migration, induce cholesterol
Fig 4. A physiologically relevant dose of the formulation can induce cholesterol efflux from humanmacrophage foam cells. Cholesterol efflux was
assessed in 24 hour [4-14C]cholesterol loaded PMA-differentiated THP-1 cells in the presence of AcLDL that were treated with ApoA-I (10 μg/ml) in the
presence of vehicle or ApoA-I in the presence of the complete formulation (+PS) or ApoA-I in the presence of the formulation lacking PS (-PS) for 24 hours.
Data were normalised to the ApoA-I, vehicle treated sample that has been arbitrarily assigned as 1. The data are presented as the mean ± SEM from three
independent experiments. Statistical analysis was performed using a one-way ANOVAwith Dunnett T3 post-hoc analysis where ** p <0.01.
doi:10.1371/journal.pone.0151057.g004
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efflux from macrophage foam cells and retard the polarisation of macrophages towards an M1
(pro-inflammatory) phenotype when assessed using a series of well-established in vitromodels
of atherosclerosis. The ability of physiologically relevant doses of this unique formulation to
beneficially modulate multiple key atherosclerotic events highlight the possibility of a nutri-
tionally orientated approach to support the prevention of early disease development.
To date, no other studies have examined the effect of a similar combination of active ingre-
dients on atherosclerosis or key processes associated with this disease although a plethora of
in vivo studies have demonstrated the anti-atherosclerotic actions of fish oils [36], cocoa
extracts [18, 19] and PS [22, 23] in isolation. However, it should be noted that polyphenols, fish
Fig 5. A physiologically relevant dose of the formulation can hinder M1 polarisation in murine
macrophages.Gene transcript levels of iNOS (a) and Arg2 (b) were assessed in Raw264.7 murine
macrophages that were treated with either vehicle (vehicle control); with IFN-γ (250 U/ml) and LPS (100 ng/
ml); with IFN-γ (250 U/ml) and LPS (100 ng/ml) in the presence of the complete formulation (+PS) or with IFN-
γ (250 U/ml) and LPS (100 ng/ml) in the presence of the formulation lacking PS (-PS) for 24 hours. Gene
transcript levels were calculated using the comparative Ct method and normalised to β-actin levels with the
values from IFN-γ and LPS treated cells given an arbitrary value of 1. The data are presented as the
mean ± SEM from five independent experiments. Statistical analysis was performed using a one-way
ANOVA with Dunnett T3 post-hoc analysis on square root-transformed data where * p <0.05, ** p <0.01 and
*** p <0.001.
doi:10.1371/journal.pone.0151057.g005
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oils and PS have all been shown to impart undesirable effects in numerous studies [25, 37–39]
although such observations may be the result of the inclusion of single agents in in vitro studies
that do not consider the potential impact of all other natural food source components, or, in
in vivo studies, other contributing factors such as the genetic make-up and the presence of vari-
ous risk factors such as elevated plasma cholesterol levels or a disrupted inflammatory state. In
light of this, and due to their ability to directly affect macrophage function [16, 20, 25], the
food ingredients used in our study were applied primarily in their natural or most available for-
mat, although in some instances individual bioactive components were also used, in a well-
established monocyte derived THP-1 macrophage model that shows a highly conserved
response with primary HMDM and in vivo evidence [29, 32, 40] and, considering the involve-
ment of macrophages at all stages of atherosclerosis [4], in order to facilitate a holistic screen-
ing approach.
We first confirmed that no adverse effects on cell viability or proliferation were apparent in
response to the application of the food ingredients to human macrophages in vitro (Fig 1).
These data also ensured that any observed changes in gene expression and/or cell behaviour
reported were not as a consequence of altered cell health. In addition, it is worthy of note that
PS have been included in the formulation to utilise their ability to reduce the absorption of die-
tary cholesterol from the intestinal lumen upon regular consumption of the supplement [24].
However, PS are known to cross the intestinal barrier albeit at low levels [41] and individual PS
such as stigmasterol and sitosterol, both of which are present in the supplement, have been
shown to elicit sometimes opposing atherosclerotic effects on macrophages in vitro [25].
Therefore, a formulation lacking PS was assessed in all of our in vitromodels to determine the
potential atherosclerotic effects of systemic PS. To this end, Figs 2, 3, 4, 5 and 6 show that no
masked anti-atherosclerotic effect can be attributed to PS and support its inclusion in the
formulation.
IFN-γ is a pro-inflammatory cytokine and is considered to be a key regulator of atheroscle-
rosis [3, 5, 42]. It is produced at prominent levels in atherosclerotic lesions by a variety of
immune cells including T-lymphocytes, natural killer T-cells and macrophages [43] and is
Fig 6. Major bioactive components associated with the complete formulation can inhibit MCP-1 inducedmigration of humanmonocytes. Cellular
migration was assessed using THP-1 monocytes that were treated with either vehicle (vehicle control) or with MCP-1 (20 ng/ml) or with MCP-1 (20 ng/ml) in
the presence of EPA (30 μg/ml), DHA (19.6 μg/ml), (+)-catechin (1.45 μg/ml), stigmasterol (SS, 10 μg/ml), campsterol (CS, 13.9 μg/ml) or β-sitosterol (β-SS,
27.2 μg/ml) for 3 hours. Monocyte migration is expressed as a fold-change compared to the proportion of cells that moved from the apical compartment into
the basolateral compartment in response to MCP-1 alone that has been arbitrarily set as 1. The data are presented as the mean ± SEM from four
independent experiments. Statistical analysis was performed using a one-way ANOVAwith Dunnett post-hoc analysis on Log transformed data where
* p <0.05, ** p <0.01 and *** p <0.001.
doi:10.1371/journal.pone.0151057.g006
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considered a promising therapeutic target due to its key role in all stages of the disease [44].
Studies by our own group have showed that IFN-γ can induce the expression of MCP-1 and
ICAM-1 in macrophages that are known to play prominent roles during the recruitment of
monocytes to the inflamed endothelium [33]. Here we show that physiologically relevant doses
of the formulation, with or without PS, can attenuate the IFN-γ induced ICAM-1 and MCP-1
expression in THP-1 monocyte derived macrophages, physiologically relevant primary
HMDM (Fig 2) and murine macrophages (S1 Fig) and may therefore prevent the recruitment
of monocytes to the inflamed endothelium—a key stage of early atheroma development. In
addition, incubation with either formulation clearly inhibits the movement of monocytes
towards MCP-1 (Fig 3) which also alludes to reduced numbers of macrophages at the site of
atheroma development and adds functionality to our observed changes in gene expression
(Fig 2). Analysis of individual bioactive components contained in the formulation suggest that
the effects on monocyte migration maybe mediated by EPA and (+)-catechin (Fig 6), an obser-
vation supported by other studies demonstrating reduced monocyte migration/adhesion in
response to various catechin isomers [45, 46] and fish oil or ω-3 PUFAs [47, 48]. Reduced
serum ICAM-1 levels in response to cocoa extract supplementation [49] and reduced transcript
levels of ICAM-1 in EPA stimulated monocytes [50] has also been previously documented.
Interestingly, our study also suggests the lack of antagonistic or synergistic effects between the
individual formulation components as both EPA and (+)-catechin (Fig 6) appear to attenuate
monocyte migration at levels comparable with the complete formulation (Fig 3) though further
experiments will be required for firm conclusions.
The formation of macrophage derived foam cells is also considered a major step in athero-
sclerosis development [4] and in recent years the underlying mechanisms have become a com-
mon target for preliminary intervention studies [29, 32]. Here we report that exposure of
cholesterol-loaded human macrophages, or foam cells, to either formulation (with or without
PS) can increase ApoA-I mediated cholesterol efflux from the cells and possibly reverse the
development of foam cells. PS and ω-3 PUFAs have both been implicated as regulators of mac-
rophage cholesterol homeostasis in other in vitro studies [17, 25] suggesting that these may be
responsible for the changes observed in our study, however, no differences in cholesterol efflux
were observed between the formulations with or without PS in our model.
It is now emerging that once in the arterial intima, macrophages can polarise into either
pro-inflammatory M1 or anti-inflammatory M2 subgroups and an the accumulation of M1
macrophages may have a detrimental effect on fibrotic plaque stability [8]. In this study we
clearly show that either formulation can hinder Raw264.7 macrophage polarisation towards
the M1 phenotype as depicted by a reduction in the expression of iNOS and Arg2; two robust
markers of the M1 phenotype [34]. This suggests that the formulation may have the potential
to help stabilise the fibrotic cap in established atherosclerosis and supports earlier studies that
have shown strong links between ω-3 PUFAs and reduced M1 phenotype formation [51, 52].
In conclusion, this is the first in vitro study to examine the effect of this combination of
nutritional ingredients and provides preliminary evidence to suggest a potential anti-
atherosclerotic effect during numerous processes associated with the disease. Furthermore, this
study provides support for future in vivo animal and/or human studies to elucidate its ability to
prevent atherosclerosis.
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